Research Output Journal of Public Health and Medicine 3(2):14-17, 2024

ROJPHM

ISSN ONLINE: 1115-9715
ISSN PRINT: 1115-6147

https://rojournals.org/roj-public-health-and-medicine/

https://doi.org/10.59298/ROJPHM/2024/321417

The Role of Probiotics in Gut Health and Disease

Mwende Wairimu G.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Gut health is widely seen as a critical component of general well-being, affected in large part by the gut microbiome, a complex collection of bacteria that live in the gastrointestinal system. Probiotics, which are live bacteria that provide health benefits when taken in suitable doses, are essential for maintaining and improving gut health. This review looks at how probiotics work, including how they modulate gut microbiota, improve intestinal barrier function, and reduce inflammation. The evidence for the advantages of probiotics in various gastrointestinal conditions, such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and antibiotic-associated diarrhoea, is discussed. The paper also discusses problems in probiotic therapy, such as strain-specific effects and optimal dose. Overall, probiotics show great potential in both preventing and treating gastrointestinal illnesses, but more study is needed to enhance treatment methods and better understand individual responses.

Keywords: Probiotics, Gut Health, Gut Microbiome, Gastrointestinal Disorders, Inflammation.

INTRODUCTION

The term "gut health" is used to describe the functioning of the gastrointestinal tract and the equilibrium between the microorganisms within it and their hosts. It was estimated that up to 100 trillion microorganisms involve the human body, outnumbering individual cells, and are established inside various mucosa-associated tissues; specifically, 10^14 bacterial cells are found in the gastrointestinal tract. The gut microbiome is confirmed as an impacting factor in human health. The defined balance of the microflora peers from mutualistic relations between the host and natural microflora, but a disbalance or a collection of aggressive helpful bacteria or a collection of microorganisms from the peculiar factor can result in irritation of the gastrointestinal system. Probiotics are currently defined as live microorganisms that, when administered in suitable amounts, encourage health benefits, but several persons are involved in the gut microbiome team while researchers are studying probiotics for their health benefits [1]. The microbial community present within the gut is estimated to weigh 1–2 kg and is constantly feeding from the surfaces and contents to grow. Most of the microorganism community that has been detected in the gut is created in the colon, comprising a different range of species, including a minority of anaerobic and facultative organisms. Many of these bacteria have positive effects on their host by producing essential vitamins, generating energy through the breakdown of macronutrients, inhibiting the spread of pathogenic organisms, improving the homeostatic state via an effect on the central nervous system, breeding helpful mucus, preserving intestinal mucin, preserving the endothelium and mucosal blood flow, promoting white adipose tissue and deposit of body fat, preserving the enteric neurotransmitters, and promoting the modification to the aging process [2].

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

UNDERSTANDING PROBIOTICS AND THEIR MECHANISMS OF ACTION

Probiotics are defined as live microorganisms that, when consumed in adequate amounts, confer a health benefit to the host. Probiotics can exert their effects through a variety of mechanisms, such as modulating the gut microbiota by outcompeting pathogenic bacteria and producing beneficial metabolites. Probiotic mechanisms of action may also include improving the function of the intestinal barrier, attenuating inflammation, and modifying immune responses. Specifically, they can inhibit the adhesion of pathogens or toxins on mucus and epithelial cell surfaces, maintaining mucus layer integrity, reducing apoptosis, and maintaining cell-tight junctions [3]. There are several probiotic strains present in commercially available probiotic products. Some common bacterial probiotics include Lactobacillus rhamnosus GG, Lactobacillus casei Shirota, and Lactobacillus acidophilus, as well as various Bifidobacterium species. Several yeasts and even non-traditional probiotics also exist. The strain designation is critical when discussing probiotics, as every strain can have unique biological effects. Some, but not all, probiotic bacteria can metabolize a wide variety of dietary macromolecules, which is one way that probiotics can interact with their human host. Probiotics also produce other biologically active metabolites, including neurotransmitters, vitamins, and short-chain fatty acids, which can help to regulate the intestinal microbiota and host metabolism. Taken together, these factors make probiotics a great choice for assessing the concept of direct impacts of live cells [4].

EVIDENCE-BASED BENEFITS OF PROBIOTICS IN MAINTAINING GUT HEALTH

Increased understanding of the gut microecosystem has made it possible to appreciate different perspectives on gut health maintenance and disease etiology. With evidence from established and advanced pilot studies, it is clear that probiotics can contribute to disease prevention and general well-being. Probiotics can enhance gut microbiota diversity, increase beneficial gut bacteria, and reduce harmful bacteria. Probiotics maintain gut microbiota homeostasis, making the internal environment more stable. Gut microbiota homeostasis is an important indicator of health status. In long-term entertainment activities, the incidence of constipation can be effectively reduced by using foods containing probiotics as an adjunct. In addition, many studies have shown that probiotics have a certain effect on bloating, flatulence, and other digestive symptoms [5]. The gastrointestinal system is equivalent to a long pipe from the mouth to the anus. If the pipe wall is damaged, a variety of external bacteria, viruses, and harmful substances can enter the body directly, which will cause great trouble to human health. The intestinal mucosa has another special structure: tight junctions. These molecules connect adjacent epithelial cells and control component penetration. These molecules can be seen as doorguards. Once they find toxic molecules or bacteria, they block their transmission. Probiotics can increase and repair tight junction molecules, thereby repairing the intestinal barrier and reducing the risk of autoimmune diseases and inflammation. In terms of anti-inflammatory ability, probiotics have anti-inflammatory effects in various intestinal diseases, including ulcerative colitis, Crohn's disease, and colon cancer caused by inflammation. Administration of probiotics shortly after antibiotic treatment can significantly shorten the time it takes for normal microbiota to recover to the pre-antibiotic state. Consequently, probiotics are effective in anti-inflammatory effects and microbiota immunity. This evidence shows that probiotics have great potential in disease prevention [6].

PROBIOTICS IN THE PREVENTION AND MANAGEMENT OF GASTROINTESTINAL DISORDERS

The gut-brain-microbiota axis consists of bidirectional communication between the gastrointestinal (GI) tract and the central or enteric nervous system, as well as the gut microbiota. The bidirectional communication between the gut and the brain is evident in the onset and course of a functional GI illness. As a cornerstone of the microbiota, probiotics—generally nonpathogenic and beneficial bacteria, yeast, or other living microorganisms—have been the subject of an increasing number of studies. Currently, probiotics have been tested in the treatment of a variety of GI diseases, such as chronic idiopathic constipation, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and infectious diarrhea. We have conducted a review of this scientific literature to confirm its effectiveness in preventing, improving, or altering the course of the diseases listed above. The studies were clinical trials or prospective observational studies. The main outcome variables were reliance, structural or psychological disability, or quality of life. It is important to note that the potency of the bacteria, duration, and dosing strategies are particularly variant in these studies, as are the study results. As a result, some authors have recommended the use of probiotic combinations containing multiple bacterial strains. Also, these authors did not recommend the use of a probiotic blend alone but also advised consulting with a GI therapist. Furthermore, we must verify the following. In the medical microbiota replacement therapy for IBD, the

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

patient's feces or another donor's feces are put into the patient's gut to start the fecal metabolism. We should always monitor signs of microorganism or virus infection, as performed before matching transplantation, to avoid severe pathogen contamination. Interest in the role of the gut microbiome and probiotics in preventing and managing a variety of gastrointestinal disorders is growing. This review outlines the conditions for which efficacy in preventing or treating disease has been suggested by randomized controlled trials or original clinical observations published in the past decade. Further research is needed to understand the optimal dosing and strains of probiotics recommended for these disorders. While some conditions are highly responsive to probiotic supplementation, such as the management of postoperative pouchitis and irritable bowel syndrome, the response rates differ somewhat by patient. The evidence suggests that probiotics are effective for managing infective diarrhea, reducing the incidence of postoperative septic complications, reducing the symptoms of irritable bowel syndrome, and slowing the progression of ulcerative colitis. Since individuals with cancer have a significantly higher risk of getting an infection and relapsing, clinically they should be considered a high category. Evidence above programs a shared decision-making approach between healthcare providers and patients to manage daily intake of probiotics as a maintenance treatment when related to those designs. A challenge in recommending probiotic interventions for these conditions is determining who, among the broadly cast patients with diseases such as IBD and IBS, might be most responsive. Not all members of a given population improve with probiotic therapy. It is important to develop approaches that enable delivery to a targeted population more likely to respond. Also, these diseases neither eliminate nor cure irritable bowel syndrome nor shorten the duration of uncomplicated diseases. Clinicians have to take into account the properties associated with probiotic combinations as part of a more comprehensive therapeutic approach, but it is not enough to use probiotic coincidences by themselves. Healthcare socializers need to hire professional collaboration according to the guidelines. Finally, very caution needs to be taken with pregnant women and newborns before proposing conflicts [7].

PROBIOTICS IN THE TREATMENT OF SPECIFIC DISEASES

In recent years, the research data on the use of probiotics and the improvement of the health condition of adults and children suffering from different pediatric diseases have increased. Therefore, research data on the use of probiotics not only in upper gastrointestinal diseases but also in several pathologies localized in different regions of the gastrointestinal tract are presented, including celiac disease, inflammatory bowel diseases, hepatic diseases, cirrhosis, abdominal surgical emergencies, and colorectal disease. Even the improvement of the general conditions, for which usually a strong placebo effect is recognizable, shows that the results between patients treated in different countries are consistent [8]. Correspondingly, the pathophysiology of many of these diseases, as well as the pathogenesis and the possibilities of their treatments, are not yet fully understood. This poor state of therapy for many of these diseases also supports the use of probiotics in their treatment, particularly through intra-intestinal or local administration. The probiotic approach is not curative and works in most of these pathologies as an adjunct to specific treatments, with the advantage of no side effects. Probiotics are microorganisms that, when administered in adequate amounts, produce beneficial effects on the health condition of the patient. The principal mechanisms of action include modulation of inflammation and mesenteric lymph nodes, inhibition of harmful bacteria, modulation of eukaryotic cellular behavior, and anti-cancer effects [9].

CONCLUSION

Probiotics represent a valuable tool in the management and prevention of various gastrointestinal disorders due to their ability to influence the gut microbiome, improve intestinal barrier function, and modulate inflammatory responses. While current evidence supports the use of probiotics for conditions such as IBS, IBD, and antibiotic-associated diarrhea, variability in individual responses and the complexity of probiotic effects necessitate further research. Future studies should focus on optimizing probiotic strains, and dosing strategies, and identifying patient populations most likely to benefit from probiotic interventions. As our understanding of the gut microbiome evolves, probiotics may become an integral component of personalized approaches to gut health and disease management.

REFERENCES

1. De Filippis F, Pasolli E, Ercolini D. The food-gut axis: lactic acid bacteria and their link to food, the gut microbiome and human health. FEMS microbiology reviews. 2020 Jul;44(4):454-89.
2. Glenny EM, Fouladi F, Thomas SA, Bulik-Sullivan EC, Tang Q, Djukic Z, Trillo-Ordonez YS, Fodor AA, Tarantino LM, M. Bulik C, Carroll IM. Gut microbial communities from patients with anorexia nervosa do not influence body weight in recipient germ-free mice. Gut Microbes. 2021 Jan 1;13(1):1897216.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

3. Chaudhari A, Dwivedi MK. The concept of probiotics, prebiotics, postbiotics, synbiotics, nutribiotics, and pharmabiotics. InProbiotics in the prevention and management of human diseases 2022 Jan 1 (pp. 1-11). Academic Press. [HTML]
4. Forssten SD, Laitila A, Maukonen J, Ouwehand AC. Probiotic triangle of success; strain production, clinical studies and product development. FEMS Microbiology Letters. 2020 Oct;367(19):fnaa167.
5. Varela-Trinidad GU, Domínguez-Díaz C, Solórzano-Castanedo K, Íñiguez-Gutiérrez L, Hernández-Flores TD, Fafutis-Morris M. Probiotics: Protecting our health from the gut. Microorganisms. 2022 Jul 14;10(7):1428.
6. Ahmadi S, Wang S, Nagpal R, Wang B, Jain S, Razazan A, Mishra SP, Zhu X, Wang Z, Kavanagh K, Yadav H. A human-origin probiotic cocktail ameliorates aging-related leaky gut and inflammation via modulating the microbiota/taurine/tight junction axis. JCI insight. 2020 May 5;5(9).
7. Barra M, Danino T, Garrido D. Engineered probiotics for detection and treatment of inflammatory intestinal diseases. Frontiers in Bioengineering and Biotechnology. 2020 Mar 31; 8:265.
8. Mai TT, Thi Thu P, Thi Hang H, Trang TT, Yui S, Shigehisa A, Tien VT, Dung TV, Nga PB, Hung NT, Tuyen LD. Efficacy of probiotics on digestive disorders and acute respiratory infections: a controlled clinical trial in young Vietnamese children. European journal of clinical nutrition. 2021 Mar;75(3):513-20.
9. Lu K, Dong S, Wu X, Jin R, Chen H. Probiotics in cancer. Frontiers in Oncology. 2021 Mar 12; 11:638148.

CITATION: Mwende Wairimu G. (2024). The Role of Probiotics in Gut Health and Disease. Research Output Journal of Public Health and Medicine 3(2):14-17. https://doi.org/10.59298/ROJPHM/2024/321417

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.